This is a post authorization observational study to monitor the utilization practices and describe the safety profile of BOTOX® in clinical practice for the prophylactic treatment of headaches in adult patients with chronic migraine.
Study Type
OBSERVATIONAL
Enrollment
1,168
155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
Unnamed facility
Munich, Germany
Unnamed facility
Oviedo, Spain
Unnamed facility
Stockholm, Sweden
Unnamed facility
London, United Kingdom
Incidence Rate of Dysphagia
Incidence rates are reported for subjects with events per 1,000 person-months and are based on the first reported occurrence of dysphagia from study enrollment up to 64 weeks. Dysphagia is difficulty or discomfort swallowing.
Time frame: 64 weeks
Incidence Rate of Intractable Migraine
Incidence rates are reported for subjects with events per 1,000 person-months and are based on the first reported occurrence of intractable migraine from study enrollment up to 64 weeks. Intractable migraine is a migraine that does not seem to go away.
Time frame: 64 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.